News

Understanding Recent Market Moves for Johnson & Johnson Shares

Understanding Recent Market Moves for Johnson & Johnson Shares

Understanding Recent Market Moves for Johnson & Johnson Shares

Financial giants have made significant bearish maneuvers recently, particularly focusing on Johnson & Johnson (NYSE: JNJ). Analyzing the options history for JNJ, we uncovered 8 unusual trades that highlight the sentiment of major players in the market.

Market Sentiment Analysis

Our in-depth analysis shows that out of the traders recently engaged, 25% expressed a bullish outlook while a notable 75% leaned towards bearish sentiment. Among the trades recorded, 4 were puts totaling approximately $229,594, while 4 calls accounted for about $214,282.

Projected Price Targets

Looking at the volume and open interest associated with these contracts, market whales appear to be focusing on a price range for JNJ that falls between $155.0 and $175.0 over the past quarter. This range indicates where the heavy hitters expect potential price movements.

Key Insights from Volume and Open Interest

Understanding the dynamics of volume and open interest is vital for traders. These metrics provide crucial insights into liquidity and interest levels concerning Johnson & Johnson's options at various strike prices. Here, we delve into the patterns observed within significant trades for JNJ's calls and puts over the last month.

Analyzing 30-Day Option Volume and Interest

Insights drawn from the past 30 days reveal a robust environment for trading JNJ options. The data showcases trends that can inform decision-making strategies for both retail and institutional investors.

Notable Options Trades for JNJ

Several large trades have caught our attention, highlighting differing trader sentiments:

1. One notable transaction involved JNJ put options characterized as a bullish move, with a value of $109.4K aimed at a $165.00 strike price expiring on 11/22/24.

2. In contrast, a bearish sentiment emerged with a significant call sweep, trading at $75.0K for a $175.00 strike price, set to expire on 09/19/25.

3. Another bearish transaction recorded puts at $53.0K with a $160.00 strike price, reflecting cautious sentiment towards Johnson & Johnson.

Overview of Johnson & Johnson

Johnson & Johnson is recognized as the world's largest and most versatile healthcare entity, with its operations split into pharmaceuticals and medical devices. Following the recent divestment of its consumer segment, Kenvue, the remaining divisions now constitute the entirety of the company's revenue stream. The pharmaceutical division is engaged in various therapeutic areas including immunology, oncology, cardiovascular, and metabolic diseases, predominantly generating revenue from the U.S. market.

Current Market Position of Johnson & Johnson

As we analyze Johnson & Johnson's current status in the market, a few key observations arise:

  • The current trading volume stands at 1,628,630, with JNJ's price reflecting a 0.81% increase, now sitting at $161.81.
  • Relative Strength Index (RSI) indicators suggest the stock remains neutral, balancing between overbought and oversold conditions.
  • An earnings announcement is anticipated shortly, expected to stir market reactions.

Analyst Perspectives on JNJ

Insights from 5 leading analysts over the last month reveal a consensus average price target set at $199.6 for JNJ shares. Recent actions include:

- Analysts from RBC Capital have notably downgraded their rating to Outperform, establishing a price target of $175.

- Nonetheless, they maintain their stance with a new target of $178.

- Additionally, Cantor Fitzgerald has adjusted its rating to Overweight, proposing a price target of $215.

Individuals engaging in options trading should remain cognizant of the associated risks yet acknowledge the potential for considerable profits. Proficient traders can mitigate these risks through consistent education, strategic adjustments, and a keen understanding of market movements. For ongoing insights into Johnson & Johnson’s options trading, signing up with reliable platforms can provide real-time updates.

Frequently Asked Questions

What trends are observed in JNJ's recent options trading?

Recent options trading shows a significant bearish trend among traders, with most leaning towards puts over calls.

What is the current trading price for Johnson & Johnson?

Currently, Johnson & Johnson shares are trading at approximately $161.81, marking a slight increase of 0.81%.

What is the average analyst price target for JNJ?

The average price target among analysts for Johnson & Johnson is set at $199.6.

What are the key segments of Johnson & Johnson's operations?

Johnson & Johnson operates primarily in pharmaceuticals and medical devices, following the divestiture of its consumer business.

How can I stay updated on JNJ options trading?

Staying informed requires utilizing educational resources and subscribing to platforms offering real-time trading insights and alerts.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 19

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Phase I of 2026 Hong Kong Trade Shows Highlights Innovation

Updated Category News Views 17

Hong Kong Takes Center Stage in Global Commerce Flip through the economic landscape today, and you’ll spot Hong Kong, decked out in its best as a trade linchpin—with over 2,100 suppliers gathered under one roof. AsiaWorld-Expo is buzzing with the commencement of Phase I of the October 2026 Global Sources Hong Kong Shows. The theme's all about 'Connecting Global...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 11

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 9

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 16

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Southern Company Sparks Swift Power Restoration Post-Isaias

Updated Category News Views 20

Well, when Mother Nature decides to throw a tantrum, it takes seasoned hands and savvy tech to clean up the mess. That's exactly what Southern Company is doing after Hurricane Isaias wreaked havoc on the Southeast. With their electric utilities—Alabama Power, Georgia Power, and Mississippi Power—hitting the ground running, they've already restored power to a whopping...

Continue Reading
AI Drives Major Time Savings in Endoscopy Tech

Updated Category News Views 17

AI in Endoscopy: Game-Changer or Gimmick? Stumbling across AnX Robotica's latest pitch about their NaviCam ProScan AI workflow, one can't help but feel a mix of curiosity and skepticism. With the stakes in medical tech sky-high, they've fired off some impressive stats that grab attention. We're talking about cutting small-bowel capsule review times by a whopping...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 15

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
NARUTO Card Game Set for June 2027 Global Launch

Updated Category News Views 18

Mark Your Calendars: Global Launch June 2027 They're rolling out a red carpet for nostalgia here, I tell ya! At the New York Comic Con, BANDAI announced a worldwide launch for the NARUTO CARD GAME in June 2027. We'll see pre-built decks starring your favorite shinobi and a mad sprint to collect with the new booster packs. Feels sort of like they’re summoning a jutsu...

Continue Reading

Top 5 Most Recently Viewed Articles

AbolerIS Pharma Continues Innovating in Autoimmune Treatments

Updated Category News Views 190

AbolerIS Pharma's Innovative Approach to Autoimmune Disorders AbolerIS Pharma, a name making waves in the biopharmaceutical sector, is dedicated to transforming lives for those grappling with autoimmune and inflammatory diseases. The company's latest innovation, ABO21009, is a unique anti-CD45RC monoclonal antibody poised to address significant gaps in treatment for...

Continue Reading
Cellectis Faces Pressure After Allogene's Arbitration Win

Updated Category News Views 156

Recent Developments Impacting Cellectis Shares Shares of Cellectis S.A. (NASDAQ: CLLS) experienced a significant decline following a favorable arbitration outcome for Allogene Therapeutics Inc. (NASDAQ: ALLO). The arbitration decision concluded in favor of Allogene's partner, Servier, which was directly related to the CAR-T therapy cemacabtagene ansegedleucel, also known...

Continue Reading
CN Announces Exciting Dividend for Its Shareholders

Updated Category News Views 82

CN's Third-Quarter Dividend Announcement CN, recognized as a leader in rail transportation, has officially declared a quarterly dividend on its common shares outstanding. The Board of Directors has approved a dividend of eighty-eight and three-quarter cents (C$0.8875) per share. This dividend will reward shareholders for their trust and investment in the company. Details...

Continue Reading
Mplify's Global NaaS Event: Shaping the Future of Connectivity

Updated Category News Views 265

Mplify's Vision for the Future of NaaS Mplify, a prominent name in the networking world, is preparing to host the highly anticipated Global Network-as-a-Service Event (GNE) in November 2025. This event will bring together leading experts and innovators focused on transforming how businesses leverage Network-as-a-Service (NaaS) in the rapidly evolving digital landscape....

Continue Reading
Euroholdings Ltd's Q3 2025 Performance and Future Growth Plans

Updated Category News Views 115

Euroholdings Ltd's Q3 2025 Performance Overview Euroholdings Ltd (NASDAQ: EHLD), a prominent player in the container shipping sector, has recently published its financial results for the third quarter and nine-month period that ended September 30, 2025. With a mission to provide efficient seaborne transportation for containerized cargo, Euroholdings made substantial...

Continue Reading